LAUSR

The cytotoxic and antitumor effect of liposomal form of silibinin was studied. It was shown that the liposomal silibinin reveals more pronounced cytotoxic activity in vitro against HeLa (cervix carcinoma), HT1080 (fibrosarcoma), and MCF-7 (breast adenocarcinoma) human tumor cell lines compared with non-liposomal silibinin. In vivo experiments demonstrated a possibility of parenteral use of the liposomal form. It was demonstrated that intravenous administration of liposomal silibinin has a significant antitumor effect in vivo against murine adenocarcinoma of Ca 755 and leads to inhibition of tumor growth (53.6%) and an increase (49.4%) in the mean life span of experimental animals compared to untreated control and animals receiving non-liposomal forms (free silibinin and its mixture with lecithin) administered orally.